3/27
08:53 am
ptix
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders [Yahoo! Finance]
Medium
Report
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders [Yahoo! Finance]
3/27
08:42 am
ptix
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Medium
Report
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
3/25
05:06 pm
ptix
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call [Yahoo! Finance]
Neutral
Report
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call [Yahoo! Finance]
3/25
04:12 pm
ptix
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Neutral
Report
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
3/21
08:46 am
ptix
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice [Yahoo! Finance]
Medium
Report
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice [Yahoo! Finance]
3/21
08:41 am
ptix
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
Medium
Report
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
3/14
03:40 am
ptix
Sensorion Reports Full-Year 2023 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Sensorion Reports Full-Year 2023 Financial Results and Business Update [Yahoo! Finance]
2/13
08:37 am
ptix
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders [Yahoo! Finance]
Medium
Report
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders [Yahoo! Finance]
2/13
08:30 am
ptix
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Medium
Report
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders